Beyond PAINs: Chemotype Sensitivity of Protein Methyltransferases in Screens.

ACS Med Chem Lett

Lilly Research Laboratories, Eli Lilly and Company , Lilly Corporate Center, Indianapolis, Indiana 46285, United States.

Published: February 2016

Screening of the relatively new target class, the lysine and arginine methyltransferases (MTases), presents unique challenges in the identification and confirmation of active chemical matter. Examination of high throughput screening data generated using Scintillation Proximity Assay (SPA) format for a number of protein MTase targets reveals sensitivity to both the known pan assay interference compounds (PAINS) and also other scaffolds not currently precedented as assay interferers. We find that, in general, true actives show significant selectivity within the MTase family. With the exception of slight modifications of SAM-like compounds, scaffolds that are observed frequently in multiple MTase assays should be viewed with caution and should be carefully validated before following up.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753540PMC
http://dx.doi.org/10.1021/acsmedchemlett.5b00375DOI Listing

Publication Analysis

Top Keywords

pains chemotype
4
chemotype sensitivity
4
sensitivity protein
4
protein methyltransferases
4
methyltransferases screens
4
screens screening
4
screening target
4
target class
4
class lysine
4
lysine arginine
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!